8-K 1 nmtr8-k21621.htm 8-K Document

Washington, D.C. 20549
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of report (Date of earliest event reported): February 12, 2021
9 Meters Biopharma, Inc.
(Exact name of registrant as specified in its charter)
Delaware 001-37797 27-3948465
(State or other jurisdiction of
incorporation or organization)
File Number)
 (I.R.S. Employer
Identification No.)
8480 Honeycutt Road, Suite 120, Raleigh, NC 27615
(Address of principal executive offices) (Zip Code)
(919) 275-1933
(Registrant’s telephone number, include area code)
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock $0.0001 Par ValueNMTRThe Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company x
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. x

Item 5.02.Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(b) On February 12, 2021, Dr. Nissim Darvish informed 9 Meters Biopharma, Inc. (the “Company”) that due to his move to a part time venture partner at Orbimed Advisors LLC (“Orbimed”), following his decision to start his own venture, he will resign from the Board of Directors (the “Board”) of the Company, effective February 12, 2021. Dr. Darvish has served as a director since May 2020. Dr. Darvish was also member of the board of directors of RDD Pharma, Ltd., an Orbimed backed company that merged with Innovate Biopharmaceuticals, Inc. in May 2020 to become 9 Meters Biopharma, Inc. Dr. Darvish’s decision to resign from the Company was based on his time commitment to his new venture and on becoming a part time venture partner at Orbimed and was not due to a disagreement with the Company on any matter relating to its operations, policies, or practices. Orbimed remains a significant investor in the Company.



Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 9 Meters Biopharma, Inc.
Date: February 16, 2021By: /s/ Edward J. Sitar
   Edward J. Sitar
   Chief Financial Officer